Salute e Benessere

Ultimovacs Updates Timeline for Reporting on Randomized UV1 Phase II Trial…

Study protocol enables readout of the INITIUM trial after all patients have been followed for a minimum of 18 months, or after 70 patients have progressed or died.As of today, the 70 events have not yet occurred, but the 18-month follow-up for the last patient has now been reached. The Company expects to announce topline results from the INITIUM trial in March 2024. The randomized Phase II clinical trial results will provide comparative data on efficacy and safety for UV1 vaccination...
Nasdaq GlobeNewswire
16/01/2024

European Commission approves Roche's Tecentriq SC, the EU's first PD-(L)1 cancer…

Subcutaneous (SC) injection offers the potential for a faster, more convenient alternative to intravenous (IV) infusion and is preferred by cancer patients, nurses and physicians 1-5 Tecentriq SC reduces treatment time by approximately 80%, compared with standard IV infusion 6 Roche is working closely with national health systems in Europe to ensure patients can access Tecentriq SC as quickly as possibleBasel, 16 January 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced...
Nasdaq GlobeNewswire
16/01/2024

Brain Navi Announces 100th Surgical Procedure Completed Using NaoTrac

Across Taiwan, there have been already several hospitals installed the system. China Medical University Hospital Neurosurgery Department Director Chun-Chung Chen said, "In the past time, we can only treat the ICH blood clot blindly, now we can plan the pathway, check in real time and complete the procedure perfectly." Another Director Dr. Jeng-Hung Guo said "NaoTrac's fast registration leads to reduce surgical procedure time and faster patient recoveries. The NaoTrac worked very…
PR Newswire
16/01/2024

Global Pharma 4.0 Market to Hit $54.43 Billion by 2031 at 18.3% CAGR: Coherent…

The key market players are focused on adopting various business development activities, such as product launches and others, which in turn is expected to propel market growth over the forecast period. For instance, on March 28, 2023, Fujitsu Limited, a pharmaceutical company, announced the launch of new cloud-based platform for healthcare sector in Japan, promoting personalized healthcare and drug development The key market players are focused on adopting various business development...
PR Newswire
16/01/2024

Increasing Concern Regarding Health and the Rising Issues Due to Imbalance in…

A proper balance in the levels of testosterone is required. High or low levels of testosterone are responsible for serious health issues. The high levels of testosterone in the females develop condition of polycystic ovary syndrome (PCOS), which is a common condition observed in every one woman among five. On the other hand, low levels of testosterone in males can lead to infertility, erectile dysfunction, and many others. The monitoring of testosterone thus becomes important in both males and…
PR Newswire
15/01/2024

Heart Failure Treatment Drug Market to Accelerate Immensely by 2032, Predicts…

Key Takeaways from the Heart Failure Market Report Key Takeaways from the Heart Failure Market Report Discover which therapies are expected to grab the major heart failure market share @Heart Failure Market Report Heart Failure Overview Heart failure, also referred to as congestive heart failure, is categorized into left-side heart failure and right-side heart failure. Cor pulmonale, another term for heart failure, indicates that elevated blood pressure in the pulmonary...
PR Newswire
15/01/2024

Lyme Disease Treatment Market is Expected to Showcase Significant Growth by…

Key Takeaways from the Lyme Disease Market Report Key Takeaways from the Lyme Disease Market Report Discover which therapies are expected to grab the major Lyme disease market share @Lyme Disease Market Report Lyme Disease Overview Lyme disease, also known as Lyme borreliosis, is an infectious disease caused primarily by the bacteriumBorrelia burgdorferi, with occasional cases attributed toBorrelia mayonii. The transmission to humans occurs through the bite of...
PR Newswire
15/01/2024

GENFIT Announces 2024 Financial Calendar  

Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), January 15, 2024-GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced its provisional financial calendar for 2024.2024 Financial CalendarFebruary 29, 2024Publication of revenue and cash position at December 31, 2023April 4, 2024 Publication of Full Year 2023...
Nasdaq GlobeNewswire
15/01/2024

Temperature Monitoring Devices Market Growth Accelerating with Rising Awareness…

The global temperature monitoring devices market registered a valuation of US$ 9.50 billion in 2023 and is projected to exhibit a growth of 6.4% over the forecast period, with an estimated valuation of US$ 17.68 billion by 2034. The global temperature monitoring devices market registered a valuation of US$ 9.50 billionin 2023and is projected to exhibit a growth of6.4%over the forecast period, with an estimated valuation of US$ 17.68 billionby 2034. Request Exclusive Sample...
PR Newswire
15/01/2024

AB Science receives notice of allowance for European patent covering masitinib…

PRESS RELEASE AB SCIENCE RECEIVES NOTICE OF ALLOWANCE FOR EUROPEAN PATENT COVERING MASITINIB UNTIL 2036 IN THE TREATMENT OF MASTOCYTOSISTHIS DECISION FURTHER STRENGTHENS MASITINIB'S INTELLECTUAL PROPERTY PROTECTION STRATEGY BASED ON MEDICAL USE PATENTSParis, January 15, 2024, 6pm CETAB Science SA(Euronext - FR0010557264 - AB) today announced that the European Patent Office has issued a Notice of Allowance for a patent relating to methods of treating severe systemic mastocytosis (i...
Nasdaq GlobeNewswire
15/01/2024

Guerbet: Financial agenda for 2024

Financial agenda for 2024Villepinte, 15 January 2024:Guerbet (FR0000032526), a global specialist in contrast agents and solutions for medical imaging, is announcing its financial agenda for 2024.Publications calendar 2023 ANNUAL REVENUE February 08, 2024,after trading2023 ANNUAL RESULTSMarch 20, 2024, after trading2024 1 STQUARTER REVENUE April 25, 2024, after tradingANNUAL SHAREHOLDERS' MEETING May 24, 2024 2024 2 NDQUARTER...
Nasdaq GlobeNewswire
15/01/2024

Transparency Notifications from Shareholders

PRESS RELEASE REGULATED INFORMATION15 January 2024, 06:00 pm CET Ghent, Belgium – 15 January 2024 – Sequana Medical NV (Euronext Brussels: SEQUA)(the " Company " or " SequanaMedical "), a pioneer in the treatment of fluid overload in liver disease, heart failure and cancer, announces today that it received a transparency notification from the shareholders listed below, notifying the number of voting rights attached to shares mentioned next to their respective names in the…
Nasdaq GlobeNewswire
15/01/2024

Chromatography Instrumentation Market Size to Hit USD 14 Billion by 2035 | Roots…

LONDON, Jan. 15, 2024 /PRNewswire/ -- The global chromatography instrumentation market is growing rapidly; it is estimated to be worth USD 7.6 billion in 2023 and is anticipated to reach USD 14 billion by 2035. It is expected to grow at a compounded annual growth rate (CAGR) of 5.3% during the forecast period from 2023 to 2035. LONDON,Jan. 15, 2024/PRNewswire/ -- The global chromatography instrumentation market is growing rapidly; it is estimated to be worth USD7.6 billion in...
PR Newswire
15/01/2024

Ophthalmic Equipment Market Worth $88.5 Billion | MarketsandMarkets™

Browse in-depth TOC on "Ophthalmic Equipment Market" Browse in-depth TOC on "Ophthalmic Equipment Market" 100 - Tables 100 - Figures 300 - Pages Ophthalmic Equipment Market Scope: The Ophthalmic Equipment Market is further segmented based on the product, end-user, and region. The vision care segment holds the largest market share during the forecast period. The world of vision correction stands tall as the leading force in the ophthalmic equipment market,...
PR Newswire
15/01/2024

Pharmaceutical Contract Manufacturing Market Size to Hit USD 140 billion by 2030…

LONDON, Jan. 15, 2024 /PRNewswire/ -- The global pharmaceutical contract manufacturing market is anticipated to be worth USD 90 billion in 2023 and is expected to reach USD 140 billion by 2030. It is estimated to grow at a compounded annual growth rate of 6.5% during the forecast period (2022-2030). LONDON,Jan. 15, 2024/PRNewswire/ -- The global pharmaceutical contract manufacturing market is anticipated to be worth USD 90 billion in 2023 and is expected to reachUSD 140 billionby...
PR Newswire
15/01/2024

Andelyn Biosciences and Armatus Bio Partner to Manufacture Suspension-Based AAV…

Both organizations, located in the well-established and growing biotech hub of Columbus, Ohio, are aligned in their belief that the rise of gene therapies will continue to advance human health. Both organizations, located in the well-established and growing biotech hub ofColumbus, Ohio, are aligned in their belief that the rise of gene therapies will continue to advance human health. Matt Niloff, Chief Commercial Officer at Andelyn Biosciences said, "We are extremely moved by Armatus...
PR Newswire
15/01/2024

Microbiome Manufacturing Market Size and Share to Surpass 187 million by 2035 |…

Microbiome Manufacturing Market Overview Microbiome Manufacturing Market Overview The global microbiome manufacturing market is growing rapidly; it is estimated to be worth around USD27 millionin 2023 and is expected to reach187 millionby 2035. It is anticipated to grow at a compounded annual growth rate (CAGR) of17%during the forecast period from 2023 to 2035. The human microbiome refers to the collection of microbial communities that includes beneficial bacteria and...
PR Newswire
15/01/2024

Botox Market Size to Hit USD 13.6 Billion by 2035 - Exclusive Report by Roots…

Global Botox Market Overview Global Botox Market Overview The globalbotox market is growing rapidly; it is estimated to be worthUSD 4.3 billionin 2023 and is anticipated to reachUSD 13.6 billionby 2035. It is expected to grow at a compounded annual growth rate (CAGR) of 10.08% during the forecast period from 2023 to 2035. Botulinum toxin, commonly known as botox, is a popular choice of cosmetic surgeons to treat skin abnormalities such as fine lines, frown lines, glabellar...
PR Newswire
15/01/2024

Dignitana signs OncoMedical for distribution in Switzerland and Liechtenstein

"Scalp cooling with DigniCap Delta is a significant advancement in quality of life for cancer patients, said Simon Dätwyler, CEO of OncoMedical. "Customers want the most advanced treatments to ensure optimal patient outcomes. We are happy to add DigniCap to our suite of top tier medical technologies and are eager to expand availability of DigniCap in this region." "Scalp cooling with DigniCap Delta is a significant advancement in quality of life for cancer patients, said…
PR Newswire
15/01/2024

mHealth Market Size is Projected to Reach USD 353.4 billion, Growing at 15.3%…

mHealth is utilized to improve patient care by enhancing research, healthcare services, and health outcomes. Devices, connections, apps, and service forms are all accessible for these. Since it facilitates remote data access for healthcare practitioners and increases patient engagement, mHealth is essential to telemedicine. mHealth is utilized to improve patient care by enhancing research, healthcare services, and health outcomes. Devices, connections, apps, and service forms are all…
PR Newswire
15/01/2024

Novo Nordisk A/S - share repurchase programme

Bagsværd, Denmark, 15 January 2024– On 6 November 2023, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 30 billion to be executed during a 12-month period beginning 1 February 2023. Under…
Nasdaq GlobeNewswire
15/01/2024

Luscii Supports Essen University Hospital on the further path to a "Smart…

Higher Patient Benefit Thanks to Digitally Supported Home CareThe fundamental benefit of telemonitoring in patient care is being investigated. The digital extension of care aims to facilitate a quicker return to the familiar home environment. Visits to the clinic outpatient department and unnecessary emergency room visits are also expected to decrease. Higher Patient Benefit Thanks to Digitally Supported Home CareThe fundamental benefit of telemonitoring in patient care is being investigated...
PR Newswire
15/01/2024

XNK Therapeutics receives EMA scientific recommendation for evencaleucel as an…

"We are very pleased with EMA's scientific recommendation. This is a necessary step in our regulatory approval journey and will make future interactions easier with the authorities," said Peter Hovstadius Chief Medical Officer at XNK. "We are very pleased with EMA's scientific recommendation. This is a necessary step in our regulatory approval journey and will make future interactions easier with the authorities," saidPeter HovstadiusChief Medical Officer at XNK. For more…
PR Newswire
15/01/2024

Groupe Casino: Authorisation from the French Ministry of the Economy under the…

Authorisation from the French Ministry of the Economy under the control of foreign investments in France Paris, 15 January 2024Casino announces that on 11 January 2024 the French Ministry of the Economy issued its decision authorising, under the control of foreign investments in France, the acquisition of control of the Group as part of its financial restructuring by the consortium (composed of EP Equity Investment III s.à r.l., Fimalac and Attestor), it being specified that the...
Nasdaq GlobeNewswire
15/01/2024
Altri  Comunicati